Bone Metastasis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Bone Metastasis – Pipeline Review, H2 2016’, provides an overview of the Bone Metastasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bone Metastasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Bone Metastasis

The report reviews pipeline therapeutics for Bone Metastasis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Bone Metastasis therapeutics and enlists all their major and minor projects

The report assesses Bone Metastasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Bone Metastasis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Bone Metastasis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bone Metastasis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ablynx NV

Alethia Biotherapeutics Inc.

Amgen Inc.

Amura Holdings Limited

Bayer AG

BiologicsMD, Inc.

ChemoCentryx, Inc.

Deciphera Pharmaceuticals, LLC

Oncobiologics, Inc.

Oncodrone BV

Osteologix Holdings Plc.

R-Pharm

Taiho Pharmaceutical Co., Ltd.

Terpenoid Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Bone Metastasis Overview 9

Therapeutics Development 10

Pipeline Products for Bone Metastasis - Overview 10

Pipeline Products for Bone Metastasis - Comparative Analysis 11

Bone Metastasis - Therapeutics under Development by Companies 12

Bone Metastasis - Therapeutics under Investigation by Universities/Institutes 13

Bone Metastasis - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Bone Metastasis - Products under Development by Companies 17

Bone Metastasis - Products under Investigation by Universities/Institutes 18

Bone Metastasis - Companies Involved in Therapeutics Development 19

Ablynx NV 19

Alethia Biotherapeutics Inc. 20

Amgen Inc. 21

Amura Holdings Limited 22

Bayer AG 23

BiologicsMD, Inc. 24

ChemoCentryx, Inc. 25

Deciphera Pharmaceuticals, LLC 26

Oncobiologics, Inc. 27

Oncodrone BV 28

Osteologix Holdings Plc. 29

R-Pharm 30

Taiho Pharmaceutical Co., Ltd. 31

Terpenoid Therapeutics Inc 32

Bone Metastasis - Therapeutics Assessment 33

Assessment by Monotherapy Products 33

Assessment by Target 34

Assessment by Mechanism of Action 36

Assessment by Route of Administration 38

Assessment by Molecule Type 40

Drug Profiles 42

AB-25E9 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

ADM-01 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

ALX-0141 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

AM-3701 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

AMG-161 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

BKM-1644 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

BKM-1740 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

BMD-3151 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

CCX-354 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

DCC-3014 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

denosumab - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

denosumab biosimilar - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Drugs to Inhibit CXCL5 for Bone Metastasis and Breast Cancer - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

LG-1980 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Monoclonal Antibodies to Inhibit SVEP1 for Bone Metastasis - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

NBS-101 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

OCD-155 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

radium Ra 223 dichloride - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

roneparstat - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

RPH-203 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

RSF-102 - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

RSF-103 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Small Molecules to Inhibit cFMS Kinase for Immunology and Oncology - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

Small Molecules to Inhibit GGDPS for Bone Metastasis and Oncology - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

TAS-115 - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

TPH-9 - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

vicrostatin - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Bone Metastasis - Dormant Projects 88

Bone Metastasis - Discontinued Products 91

Bone Metastasis - Product Development Milestones 92

Featured News & Press Releases 92

May 18, 2016: Bayer to Showcase Latest Data on Xofigo (radium Ra 223 dichloride) at ASCO 2016 92

Mar 29, 2016: Bayer Receives Approval for Xofigo in Japan 93

Feb 03, 2016: NICE issues full guidance for Xofigoq (radium-223 dichloride) 94

Sep 14, 2015: Bayer to Present Data On Radium-223 Dichloride at ECC2015 in Vienna 95

Jul 06, 2015: R-Pharm Group of Companies Develops Original drug for Treatment of Metastatic Bone Disease 96

Oct 09, 2013: Medivir: Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders 97

Oct 01, 2013: Goodwin Biotechnology Announces the Return of AB-25E9 Monoclonal Antibody Project from Alethia Biotherapeutics 98

Jul 17, 2013: The New England Journal of Medicine publishes results from the phase III ALSYMPCA study of Xofigo 98

Jun 20, 2013: Algeta Opens Commercial Production Facility For Xofigo Injection In Kjeller, Norway 99

May 30, 2013: Algeta Announces First Sale Of Xofigo In US 100

Feb 15, 2013: Algeta Presents Further Sub-analysis Of Phase III ALSYMPCA Study Of Radium-223 Dichloride At 2013 Genitourinary Cancers Symposium 101

Jan 14, 2013: US Nuclear Regulatory Commission Issues Licensing Decision For Radium-223 Dichloride 102

Sep 17, 2012: Bayer To Present Data On Alpharadin At ESMO 2012 Congress 102

Aug 21, 2012: Medivir Commences Phase Ib Trial Of MIV-711 For Treatment Of Skeletal Disorders 103

Jun 04, 2012: Bayer Reports Updated Data From Phase III Study Of Alpharadin For Treatment Of Prostate Cancer 103

Appendix 106

Methodology 106

Coverage 106

Secondary Research 106

Primary Research 106

Expert Panel Validation 106

Contact Us 106

Disclaimer 107

List of Tables

List of Tables

Number of Products under Development for Bone Metastasis, H2 2016 10

Number of Products under Development for Bone Metastasis – Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Clinical Stage Development, H2 2016 15

Comparative Analysis by Early Stage Development, H2 2016 16

Products under Development by Companies, H2 2016 17

Products under Investigation by Universities/Institutes, H2 2016 18

Bone Metastasis – Pipeline by Ablynx NV, H2 2016 19

Bone Metastasis – Pipeline by Alethia Biotherapeutics Inc., H2 2016 20

Bone Metastasis – Pipeline by Amgen Inc., H2 2016 21

Bone Metastasis – Pipeline by Amura Holdings Limited, H2 2016 22

Bone Metastasis – Pipeline by Bayer AG, H2 2016 23

Bone Metastasis – Pipeline by BiologicsMD, Inc., H2 2016 24

Bone Metastasis – Pipeline by ChemoCentryx, Inc., H2 2016 25

Bone Metastasis – Pipeline by Deciphera Pharmaceuticals, LLC, H2 2016 26

Bone Metastasis – Pipeline by Oncobiologics, Inc., H2 2016 27

Bone Metastasis – Pipeline by Oncodrone BV , H2 2016 28

Bone Metastasis – Pipeline by Osteologix Holdings Plc., H2 2016 29

Bone Metastasis – Pipeline by R-Pharm, H2 2016 30

Bone Metastasis – Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 31

Bone Metastasis – Pipeline by Terpenoid Therapeutics Inc, H2 2016 32

Assessment by Monotherapy Products, H2 2016 33

Number of Products by Stage and Target, H2 2016 35

Number of Products by Stage and Mechanism of Action, H2 2016 37

Number of Products by Stage and Route of Administration, H2 2016 39

Number of Products by Stage and Molecule Type, H2 2016 41

Bone Metastasis – Dormant Projects, H2 2016 88

Bone Metastasis – Dormant Projects (Contd..1), H2 2016 89

Bone Metastasis – Dormant Projects (Contd..2), H2 2016 90

Bone Metastasis – Discontinued Products, H2 2016 91

List of Figures

List of Figures

Number of Products under Development for Bone Metastasis, H2 2016 10

Number of Products under Development for Bone Metastasis – Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 16

Assessment by Monotherapy Products, H2 2016 33

Number of Products by Top 10 Targets, H2 2016 34

Number of Products by Stage and Top 10 Targets, H2 2016 34

Number of Products by Top 10 Mechanism of Actions, H2 2016 36

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 36

Number of Products by Routes of Administration, H2 2016 38

Number of Products by Stage and Routes of Administration, H2 2016 38

Number of Products by Molecule Types, H2 2016 40

Number of Products by Stage and Molecule Types, H2 2016 40

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports